• 1
    Jenkins V, Catt S, Banerjee S, Gourley C, Montes A, Solis-Trapala I, et al. Patients’ and oncologists’ views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. Br J Cancer 2013;108:226471.
  • 2
    Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013;31:4957.
  • 3
    Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.. Ann Intern Med 2012;157:9004.
  • 4
    Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta -analysis. Gynaecol Oncol 2013;130:67481.
  • 5
    Wardle J, Pope R. The psychological costs of screening for cancer. J Psychosom Res 1992;36:60924.
  • 6
    Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs I, Kilkerr J, et al. Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer 2010;103:45461.
  • 7
    Wardle J, Collins W, Pernet A, Whitehead M, Bourne T, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993;85:6537.
  • 8
    Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening-current status, future directions. Gynecol Oncol 2014;132:4905.
  • 9
    Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. Recruitment to multicentre trials – lessons from UKCTOCS: descriptive study. BMJ 2008;337:12836.
  • 10
    Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G. Manual for the Stait-Trait Anxiety Inventory (Form Y1–Y2). Palo Alto, CA: Consulting Psychology Press; 1983.
  • 11
    Goldberg D. Manual of the General Health Questionnaire. Windsor: NFER-Nelso, 1978.
  • 12
    Collins RE, Lopez LM, Marteau TM. Emotional impact of screening: a systematic review and meta- analysis. BMC Public Health 2011;11:603.
  • 13
    Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006;95:27993.
  • 14
    Jorm AF. Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychol Med 2000;30:1122.
  • 15
    Gross JJ, Carstensen LL, Pasupathi M, Tsai J, Skorpen CG, Hsu AYC. Emotion and aging: experience, expression and control. Psychol Aging 1997;12:5909.
  • 16
    Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal and ovarian cancer screening trial. J Natl Cancer Inst 2004;96:108394.
  • 17
    Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D, Phelps C, et al. Withdrawal from familial ovarian cancer screening for surgery: findings from a psychological evaluation study (PsyFOCS). Gynecol Oncol 2012;124:15863.
  • 18
    Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers M, Lancastle D, et al. Psychological outcomes of familial ovarian cancer screening: no evidence of long term harm. Gynecol Oncol 2012;127:55663.